Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI

Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI

[at noodls] – Download PDF Study Meets Primary Endpoint Conference Call and Webcast Today at 9:00 A.M. ET to Discuss Results CHICAGO– Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced preliminary, top-line results … more

View todays social media effects on DRTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Durata is hiring next, click here to view

Share this post

Comments (0)